JPS649291B2 - - Google Patents
Info
- Publication number
- JPS649291B2 JPS649291B2 JP22301782A JP22301782A JPS649291B2 JP S649291 B2 JPS649291 B2 JP S649291B2 JP 22301782 A JP22301782 A JP 22301782A JP 22301782 A JP22301782 A JP 22301782A JP S649291 B2 JPS649291 B2 JP S649291B2
- Authority
- JP
- Japan
- Prior art keywords
- pretreatment
- laxative
- colon
- present
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008141 laxative Substances 0.000 claims description 21
- 230000002475 laxative effect Effects 0.000 claims description 15
- 229960005077 sodium picosulfate Drugs 0.000 claims description 8
- GOZDTZWAMGHLDY-UHFFFAOYSA-L sodium picosulfate Chemical compound [Na+].[Na+].C1=CC(OS(=O)(=O)[O-])=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS([O-])(=O)=O)C=C1 GOZDTZWAMGHLDY-UHFFFAOYSA-L 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000006193 liquid solution Substances 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 description 8
- 229940125722 laxative agent Drugs 0.000 description 6
- 238000012084 abdominal surgery Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 229960005336 magnesium citrate Drugs 0.000 description 3
- 235000002538 magnesium citrate Nutrition 0.000 description 3
- 239000004337 magnesium citrate Substances 0.000 description 3
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 3
- 208000019399 Colonic disease Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 229930186851 sennoside Natural products 0.000 description 1
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、大腸検査や腹部外科手術時等におけ
る前処置用の下剤に関する。
近年、我国での大腸疾患、例えば、大腸がん、
大腸ポリープ、潰瘍性大腸炎、大腸クローン病等
の増加は著しく、大腸疾患に対する診断が上部消
化管同様に微細診断まで求められるようになつて
おり、その意味で大腸内視鏡やＸ線造影検査等に
よる正確な診断の重要性が高まつている。そし
て、かゝる大腸検査において正確な検査データを
得るためには、検査に際しての適切で、かつ患者
に対する負担の少ない前処置が必要であり、この
前処置の如何が大腸内の微細構造の描出の良・不
良に非常な影響を与えることが知られている。ま
た、腹部外科手術に際しても腸管内容物を十分に
排除する前処置が必要である。
従来、大腸検査や腹部外科手術時の前処置のた
めには、クエン酸マグネシウム液250mlとビサコ
ジル錠、センノサイド錠等の緩下剤を併用する方
法が頻用されているが、クエン酸マグネシウム液
は異味であり、かつ余りに大量であるため、服用
後の悪心、嘔吐や腹痛等の副作用があり、あるい
は全量服用が不能で十分な検査ができないといつ
た問題点があつた。
本発明者らは、前記欠点を有しない前処置用下
剤を開発すべく鋭意研究の結果、緩下剤のピコス
ルフアートナトリウムが、非常に好ましい前処置
用の下剤となることを知見し、本発明に到達し
た。
即ち、本発明は、ピコスルフアートナトリウム
を有効成分とする前処置用の下剤である。
本発明におけるピコスルフアートナトリウム
（化学名：４，4′―（２―ピリジル―メチレン）
ジフエノールビス（ソジウムスルフアート）モノ
ハイドレート）は、通常、水溶液として緩下剤に
用いられている。市販品としては、例えば１ml中
にピコスルフアートナトリウムを7.5mg含有する
ラキソベロン液（帝人医薬(株)製）が知られてい
る。緩下剤として使用する場合には、通常・成人
に対して１日１回10〜15滴（0.67〜1.0ml）が用
いられる。
本発明においては、ピコスルフアートナトリウ
ムの一回当りの服用量は、約37〜150mg、好まし
くは50〜100mg（ラキソベロン液として約５〜20
ml）が適当であり、これは、公知の手段で水剤と
して調製するのが好ましい。
本発明の前処置用の下剤は、少量の無味無臭の
ピコスルフアートナトリウムからなつているの
で、しかも水剤として調製できるので、服用が簡
単であり、副作用もほとんどなく、大腸検査や腹
部外科手術時等に際し、大腸の内容物を十分に排
泄させ、大腸を清浄化することができる。
以下、実施例により本発明を詳述する。
実施例
大腸検査が必要な複数の患者に、前処置用の下
剤（本発明の前処置用下剤と、比較として従来の
前処置用下剤を用いた）を服用させ、残渣の程度
（内視鏡検査とＸ線検査）、Ｘ線による網目像の描
出程度及び副作用の程度等を検討した。
前処置はBrownの変法に準じて前日の昼食よ
り食餌制限を行ない、午後９時に前処置用の下剤
を服用させ、午後11時に緩下剤ソルベン（小野薬
品(株)製）４錠を服用させた。本発明の前処置用の
下剤は75mg（ラキソベロン液として10ml）を服用
させ（本発明）、公知の前処置用下剤としては、
マグコロール（堀井薬品工業(株)製）を250ml服用
させた（比較例）。その後、大腸Ｘ線検査又は大
腸フアイバースコープ（内視鏡）による検査を行
なつた。
なお、マグコロールは、250ml中にクエン酸マ
グネシウムを約34ｇ含有している。
(1) Ｘ線検査と内視鏡検査による残渣の程度は、
第１表に示した通りであつた。 本発明の前処
置用の下剤は、公知のものと同程度の残渣の程
度を示し、十分に実用に耐えることがわかる。
なお、残渣の程度は、全大腸のうち最も残渣
の多い部分について、固形と液状の残渣を総合
して検討した。
The present invention relates to a laxative for pretreatment during colon examinations, abdominal surgery, etc. In recent years, colon diseases in Japan, such as colon cancer,
Colon polyps, ulcerative colitis, colon Crohn's disease, etc. are increasing significantly, and the diagnosis of colon diseases has become as detailed as the upper gastrointestinal tract. The importance of accurate diagnosis is increasing. In order to obtain accurate test data in such colon examinations, it is necessary to perform appropriate pretreatments for the examination that are less invasive to the patient. It is known that it has a great influence on the quality of products. In addition, pretreatment to sufficiently remove intestinal contents is necessary during abdominal surgery. Conventionally, for pretreatment during colon examinations or abdominal surgery, the method of using 250 ml of magnesium citrate solution in combination with laxatives such as bisacodyl tablets or sennoside tablets has been frequently used, but magnesium citrate solution has an unpleasant taste. , and because it was in such a large amount, there were problems such as side effects such as nausea, vomiting, and abdominal pain after taking it, or the inability to take the entire amount and conduct adequate tests. As a result of intensive research to develop a laxative for pretreatment that does not have the above-mentioned drawbacks, the present inventors discovered that sodium picosulfate, a laxative, is a highly preferable laxative for pretreatment. Reached. That is, the present invention is a pretreatment laxative containing sodium picosulfate as an active ingredient. Sodium picosulfate (chemical name: 4,4′-(2-pyridyl-methylene) in the present invention)
Diphenol bis(sodium sulfate) monohydrate) is usually used in laxatives as an aqueous solution. As a commercially available product, for example, Laxoberone liquid (manufactured by Teijin Pharmaceutical Co., Ltd.) containing 7.5 mg of sodium picosulfate per ml is known. When used as a laxative, 10 to 15 drops (0.67 to 1.0 ml) are usually used once a day for adults. In the present invention, the dose per dose of sodium picosulfate is about 37 to 150 mg, preferably 50 to 100 mg (about 5 to 20 mg as laxoberone solution).
ml), which are preferably prepared as aqueous solutions by known means. The pretreatment laxative of the present invention consists of a small amount of tasteless and odorless sodium picosulfate, and can be prepared as a liquid solution, making it easy to take and having almost no side effects, making it ideal for colon examinations and abdominal surgeries. When necessary, the contents of the large intestine can be sufficiently excreted and the large intestine can be cleaned. Hereinafter, the present invention will be explained in detail with reference to Examples. Example A plurality of patients requiring colon examination were given pretreatment laxatives (the pretreatment laxative of the present invention and a conventional pretreatment laxative were used as a comparison), and the degree of residue (endoscopy (examination and Pretreatment was carried out according to Brown's modified method, with dietary restrictions starting from lunch the previous day, pretreatment laxatives taken at 9 p.m., and 4 tablets of the laxative Solven (manufactured by Ono Pharmaceutical Co., Ltd.) at 11 p.m. . The laxative for pretreatment of the present invention is administered at a dose of 75 mg (10 ml as laxoberone solution) (the present invention), and known laxatives for pretreatment include:
250 ml of Magcorol (manufactured by Horii Pharmaceutical Co., Ltd.) was administered (comparative example). Thereafter, a colon X-ray examination or a colon fiberscope (endoscope) examination was performed. Furthermore, Magkororu contains approximately 34g of magnesium citrate per 250ml. (1) The degree of residue from X-ray examination and endoscopy is as follows:
The results were as shown in Table 1. It can be seen that the pretreatment laxative of the present invention shows the same level of residue as known ones, and is sufficiently durable for practical use. The degree of residue was examined by considering solid and liquid residues in the part of the entire large intestine that had the most residue.
【表】
※；−〜は残渣の程度を表わし、
−と＋は良好な前処置であ
り、は診断が困難な程度に残
渣があることを示す。
(2) Ｘ線による網目像の描出程度は、最も描出さ
れやすい横行結腸で検討したところ、本発明の
前処置用の下剤を用いた場合は、34例（65.4
％）が、比較例では28例（56.0％）が明瞭であ
つた。また、バリウムの付着性も、本発明の場
合は50例（96.2％）が、比較例では47例（94.0
％）が良好であつた。
(3) 前処置用の下剤が服用後の副作用は、第２表
に示した通りであつた。本発明のものは公知の
ものに比し、副作用、特に嘔気と嘔吐が著しく
軽減されていることがわかる。[Table] *; - ~ represents the degree of residue,
- and + are good pretreatments.
or indicates that there is a residue that is difficult to diagnose.
(2) The degree of visualization of mesh images by X-rays was investigated in the transverse colon, where it is most easily visualized.
%) was clear in 28 cases (56.0%) of the comparative examples. In addition, barium adhesion was observed in 50 cases (96.2%) in the case of the present invention and in 47 cases (94.0%) in the comparative example.
%) was good. (3) The side effects after taking pretreatment laxatives were as shown in Table 2. It can be seen that side effects, particularly nausea and vomiting, are significantly reduced in the product of the present invention compared to known products.
Claims (1)
る前処置用の下剤。 ２ １回の投与分としてピコスルフアートナトリ
ウム約37〜150mgを含有する、特許請求の範囲第
１項記載の前処置用の下剤。 ３ 剤型が水剤である特許請求の範囲第１項又は
２項記載の前処置用の下剤。[Claims] 1. A laxative for pretreatment containing sodium picosulfate as an active ingredient. 2. A pretreatment laxative according to claim 1, containing about 37 to 150 mg of sodium picosulfate per dose. 3. The laxative for pretreatment according to claim 1 or 2, which is in the form of a liquid solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22301782A JPS59112918A (en) | 1982-12-21 | 1982-12-21 | Cathartic for pretreatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22301782A JPS59112918A (en) | 1982-12-21 | 1982-12-21 | Cathartic for pretreatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59112918A JPS59112918A (en) | 1984-06-29 |
| JPS649291B2 true JPS649291B2 (en) | 1989-02-16 |
Family
ID=16791520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP22301782A Granted JPS59112918A (en) | 1982-12-21 | 1982-12-21 | Cathartic for pretreatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59112918A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101423005B1 (en) | 2013-10-17 | 2014-07-28 | 강윤식 | Bowel Cleansing Composition |
-
1982
- 1982-12-21 JP JP22301782A patent/JPS59112918A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59112918A (en) | 1984-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100297264A1 (en) | Bowel purgative and uses thereof | |
| JP5910501B2 (en) | Solution for oral administration and composition for gastrointestinal tract imaging used for CT colonography | |
| JP6782281B2 (en) | Sulfate as a transit time enhancer | |
| EP1976520B1 (en) | Kit comprising an osmotic laxative and a stimulant laxative for preparing the colon for virtual colonoscopy | |
| Filippone et al. | Obscure gastrointestinal bleeding and small bowel pathology: comparison between wireless capsule endoscopy and multidetector-row CT enteroclysis | |
| JPS649291B2 (en) | ||
| JP2009256371A (en) | Composition for imaging digestive tract in ct colonography | |
| US20130052143A1 (en) | Liquid preparation for oral administration to be used in ct colonography, and composition for digestive tract imaging | |
| JP4995369B2 (en) | X-ray contrast medium contrast-improving agent, intestinal irrigation compound and intestinal irrigation kit | |
| CN112870382A (en) | Arabinose and silicone oil type antifoaming agent combination for bowel preparation | |
| Sandikcioglu et al. | Contrast radiography in small bowel obstruction: A randomized trial of barium sulfate and a nonionic low-osmolar contrast medium | |
| JP5696326B2 (en) | CT colonography test medicine | |
| JP2005002006A (en) | Composition for contrastradiography of alimentary canal in ct colonography | |
| Reynolds et al. | Oral cholecystography with iopanoic acid (Telepaque) | |
| JP5280415B2 (en) | X-ray contrast medium contrast-improving agent, intestinal irrigation compound and intestinal irrigation kit | |
| WO2004087218A1 (en) | Agent for imporivng function of detecting lesion in digestive tract by ct colonography or mr colonography, composition for washing intestinal tract and kit or packaged article for washing intestinal tract | |
| Spada et al. | Preparations for PillCam colon capsule endoscopy are as acceptable and safe as that for standard colonoscopy | |
| JPH0121811B2 (en) | ||
| Rey et al. | Diagnosis yield of new approaches for small bowel examinations | |
| Derovs et al. | 2L of Polyethylene Glycol as the Main Small Bowel Cleansing Regimen Component Prior to Video Capsule Endoscopy: Interim Analysis | |
| Ruff et al. | Initial Experience with a New Double Balloon Colonoscope in Patients with Prior Incomplete Colonoscopy | |
| Salzman et al. | Examination of the colon using a synthetic purgative | |
| Case | Some Clinical Aspects of Cholecystography | |
| Amster | The X-Ray in Diagnosis of Diseases of the Stomach—With Lantern Slide Demonstration | |
| Bassir et al. | Long-term experience in using iotrolan for paediatric gastrointestinal studies |